SCHEMBL274368

SCHEMBL274368

Cc1ccc(S(=O)(=O)Cl)cc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 2/20 0.56
CRHBP P24387 1/20 0.56
CRHR2 Q13324 1/20 0.56
ALDH1A1 P00352 7/20 0.55
TSHR P16473 2/20 0.55
CYP3A4 P08684 1/20 0.55
RECQL P46063 1/20 0.55
HTT P42858 1/20 0.52
CCR2 P41597 3/20 0.50
KDM4E B2RXH2 2/20 0.50
MAPK1 P28482 1/20 0.50
POLB P06746 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
PKM P14618 1/20 0.48
GFER P55789 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30430459 1.00 MCOLN3 (0.56) MCOLN3CRHBPCRHR2ALDH1A1TSHR
SCHEMBL1828638 0.85 MAPT (0.51) MCOLN3CRHBPCRHR2ALDH1A1TSHR
SCHEMBL7536109 0.83 CA2 (0.46) MCOLN3CRHBPCRHR2ALDH1A1HTT
SCHEMBL10700954 0.83 MCOLN3 (0.58) MCOLN3CRHBPCRHR2ALDH1A1TSHR
SCHEMBL29397077 0.83 MCOLN3 (0.58) MCOLN3CRHBPCRHR2ALDH1A1TSHR
SCHEMBL994972 0.83 MCOLN3 (0.58) MCOLN3CRHBPCRHR2ALDH1A1TSHR
SCHEMBL3813276 0.82 VCAM1 (0.50) ALDH1A1TSHRCYP3A4HTTKDM4E
SCHEMBL731102 0.81 MCOLN3 (0.60) MCOLN3CRHBPCRHR2ALDH1A1TSHR
SCHEMBL6039257 0.81 MCOLN3 (0.56) MCOLN3CRHBPCRHR2ALDH1A1TSHR
SCHEMBL1156340 0.81 CA2 (0.66) MCOLN3CRHBPCRHR2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118420495-A Method for continuously preparing 3-nitro-4-methylbenzenesulfonyl chloride 金华双宏化工有限公司 2024-08-02 CN claimed
CN-116589384-A Method for synthesizing 3-nitro-4-methylbenzenesulfonyl chloride by utilizing microchannel reactor 贵州微化科技有限公司 2023-08-15 CN claimed
CN-109516987-B Preparation method of avibactam intermediate 江西富祥药业股份有限公司 2020-07-24 CN claimed
JP-58118558-A None JP disclosed
JP-58219159-A None JP disclosed
US-20250223266-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-10 US disclosed
CN-119930484-A Synthesis method of 4-methylsulfonyl toluene derivative 辽宁龙田化工科技有限公司 2025-05-06 CN disclosed
US-12129236-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-29 US disclosed
CN-112979631-B PARG inhibiting compounds 癌症研究科技有限公司 2024-09-20 CN disclosed
CN-118420495-A Method for continuously preparing 3-nitro-4-methylbenzenesulfonyl chloride 金华双宏化工有限公司 2024-08-02 CN disclosed
CN-118420495-A Method for continuously preparing 3-nitro-4-methylbenzenesulfonyl chloride 金华双宏化工有限公司 2024-08-02 CN disclosed
US-4229370-A INHIBITORS OF THE COMPLEMENT SYSTEM, IMMUNOLOGY AMERICAN CYANAMID COMPANY (US) 1980-10-21 US disclosed
US-4229372-A INHIBITORS OF THE COMPLEMENT SYSTEM, IMMUNOLOGY AMERICAN CYANAMID COMPANY (US) 1980-10-21 US disclosed
EP-0008154-A1 Ureylene phenylene anionic naphthalene-sulfonic acids, their use as complement system inhibitors in a body fluid and process for their preparation AMERICAN CYANAMID COMPANY (US) 1980-02-20 EP disclosed
US-4189486-A FUNGICIDES CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 1980-02-19 US disclosed
US-4180587-A Ureylene phenylene anionic naphthalenesulfonic acids as complement inhibitors AMERICAN CYANAMID COMPANY (US) 1979-12-25 US disclosed
US-4155930-A Ureylene phenylene anionic naphthalenesulfonic acids AMERICAN CYANAMID COMPANY (US) 1979-05-22 US disclosed
US-4155931-A COMPLEMENT INHIBITORS FOR MAMMALS AMERICAN CYANAMID COMPANY (US) 1979-05-22 US disclosed
US-4060549-A Process for preparing sulfonic acid fluorides BAYER AKTIENGESELLSCHAFT (DT) 1977-11-29 US disclosed
US-4036838-A Process for the production of nitro derivatives of aromatic compounds BAYER AKTIENGESELLSCHAFT (DT) 1977-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129236-B2 PARG inhibitory compounds PARP11, PARG, PARP16 MCOLN3 3996/4885CRHBP 3601/4885CRHR2 3807/4885
US-20250223266-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 MCOLN3 4157/4885CRHBP 3569/4885CRHR2 3827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.